HIGH RESOLUTION ULTRASOUND SYSTEM FOR CARDIOVASCULAR PHENOTYPING IN MICE

用于小鼠心血管表型分析的高分辨率超声系统

• 批准号: 7794207
• 负责人: ATTILA KOVACS
• 金额: $ 27.2万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-26 至 2011-07-25
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7794207
• 关键词: Animals; Arts; Biomedical Research; Blood Vessels; Cardiac; Cardiovascular Diseases; Cardiovascular system; Core Facility; Development; Discipline; Disease; Ensure; Equipment; Evaluation; Experimental Animal Model; Funding; Genes; Genetic Techniques; Goals; Heart; Housing; Human; Human Genome Project; Image; Laboratories; Lead; Molecular Genetics; Mus; Organ; Participant; Phenotype; Play; Process; Request for Proposals; Research; Research Personnel; Research Project Grants; Resolution; Role; Schools; Scientist; Structure; System; Therapeutic Intervention; Ultrasonography; United States National Institutes of Health; Universities; Washington; Work; common treatment; gene function; heart function; hemodynamics; human disease; in vivo; medical schools; mouse model; public health relevance; research study; success

DESCRIPTION (provided by applicant): This proposal requests support for the upgrade of an existing ultrasound system to the VisualSonics Vevo 2100 Imaging Platform, which will be used for structural and functional analysis of the cardiovascular system in experimental animal models of common human cardiovascular diseases. It will be housed and operated in the Mouse Cardiovascular Phenotyping Core facility of the Center for Cardiovascular Research at Washington University School of Medicine. This dedicated in vivo micro-imager will markedly advance the capabilities of the Cardiovascular Phenotyping Core, which has evolved to a highly successful, large volume facility, performing nearly 1,500 echocardiographic studies annually. It has served large number researchers from a wide variety of disciplines across multiple departments and schools at Washington University, as well as nationwide. Indeed, the users' work depends on the availability of high quality echocardiographic analysis. As a result of the quality and success of the research projects of the Core users, there has been a steady rise in the volume and complexity of the echocardiographic studies over the years to the point that the existing system can no longer adequately satisfy the demands of the User Group on the scale and scope that is required for the scientific needs of the participant. The VisualSonics Vevo 2100 is a highly versatile ultrasound system capable of providing researchers with the ability to visualize and quantify small animal anatomical targets, hemodynamics, and therapeutic interventions with resolution down to 30 microns. Its state-of-the-art technical features are uniquely suited for cardiovascular phenotyping in genetically manipulated mice. Upgrade to the new ultrasound system will provide immediate benefit to the Core users in accomplishing the scientific goals of their NIH funded projects. PUBLIC HEALTH RELEVANCE: Recent advances in biomedical research have revolutionized our basic understanding of human diseases. The human genome project holds great promise in developing breakthrough treatments for common illnesses, a promise that can only be fulfilled if we can understand how changes in the function of genes through their products lead to altered cellular and organ function, and how these changes cause disease. The use of sophisticated molecular genetic techniques in animals (mainly mice), allows scientist to study the effect of perturbation of a single gene on the function of a whole organ, including the heart and the vasculature. Stateof- the-art imaging equipments, such as the requested ultrasound machine, will play a critical role in this process of discovery. Cardiac ultrasound is uniquely suited to satisfy the diverse needs of these experiments, and has proven to be a critical asset in the evaluation of the structure and function of the heart and blood vessels in mouse models of cardiovascular disease. Our laboratory has been at the forefront of these developments and acquisition of the requested equipment will help ensure continued success of the research projects of our NIH funded investigators.

描述（由申请人提供）：该提案请求支持将现有超声系统升级为 VisualSonics Vevo 2100 成像平台，该平台将用于人类常见心血管疾病实验动物模型中心血管系统的结构和功能分析。它将在华盛顿大学医学院心血管研究中心的小鼠心血管表型分析核心设施中安置和运行。这款专用体内显微成像仪将显着提高心血管表型分析核心的功能，该核心已发展成为一个非常成功的大容量设施，每年进行近 1,500 项超声心动图研究。它为华盛顿大学以及全国多个院系和学院的大量研究人员提供了服务。事实上，用户的工作取决于高质量超声心动图分析的可用性。由于核心用户研究项目的质量和成功，多年来超声心动图研究的数量和复杂性稳步上升，以至于现有系统不再能够充分满足用户组对参与者科学需求所需的规模和范围的要求。 VisualSonics Vevo 2100 是一款高度通用的超声系统，能够为研究人员提供可视化和量化小动物解剖目标、血流动力学和治疗干预的能力，分辨率低至 30 微米。其最先进的技术特点特别适合基因改造小鼠的心血管表型分析。升级到新的超声系统将为核心用户带来立竿见影的好处，帮助其实现 NIH 资助项目的科学目标。 公共卫生相关性：生物医学研究的最新进展彻底改变了我们对人类疾病的基本理解。人类基因组计划在开发针对常见疾病的突破性治疗方法方面拥有巨大前景，只有我们能够了解基因功能通过其产物的变化如何导致细胞和器官功能改变，以及这些变化如何导致疾病，才能实现这一承诺。在动物（主要是小鼠）中使用复杂的分子遗传学技术，使科学家能够研究单个基因的扰动对整个器官（包括心脏和脉管系统）功能的影响。最先进的成像设备，例如所需的超声波机，将在这一发现过程中发挥关键作用。心脏超声特别适合满足这些实验的不同需求，并已被证明是评估心血管疾病小鼠模型心脏和血管的结构和功能的关键资产。我们的实验室一直处于这些发展的最前沿，购买所需的设备将有助于确保我们 NIH 资助的研究人员的研究项目持续取得成功。